Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective

Costs of hemophilia A treatment are increasing. Waste of clotting products should be avoided. To estimate the first-year waste of emicizumab prophylaxis for people with hemophilia A and inhibitors (PwHAi) who failed immune tolerance induction (ITI), in Brazil. We evaluated the manufacturer and the B...

Full description

Bibliographic Details
Main Authors: Ricardo Mesquita Camelo, Mariana Michel Barbosa, Luila Clicia Moura Henriques, Antony Paul Martin, Brian Godman, Augusto Afonso Guerra Júnior, Francisco de Assis Acurcio, Juliana Alvares-Teodoro
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Saudi Pharmaceutical Journal
Subjects:
hemophilia A
emicizumab
prophylaxis
waste
budget impact
Online Access:http://www.sciencedirect.com/science/article/pii/S1319016423003626

Internet

http://www.sciencedirect.com/science/article/pii/S1319016423003626

Similar Items